Nucleoside Patents (Class 435/87)
  • Patent number: 7294486
    Abstract: There is described a process for the synthesis of a fluoronucleoside compound, said process comprising mixing a substrate and an enzyme from Streptomyces cattelya as catalyst. The process may be used to produce an 18F labelled fluoronucleoside compound. There is also described an enzyme derived from Streptomyces cattelya which has the capacity to catalyse the synthesis of a fluoronucleoside compound.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: November 13, 2007
    Assignee: The University Court of the University of St. Andrews
    Inventors: David O'Hagan, Christoph Schaffrath
  • Patent number: 7270980
    Abstract: Compounds and methods for diagnosing prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate tumor protein. The inventive polypeptides may be used to generate antibodies useful for the diagnosis and monitoring of prostate cancer. Nucleic acid sequences for preparing probes, primers, and polypeptides are also provided.
    Type: Grant
    Filed: January 15, 1999
    Date of Patent: September 18, 2007
    Assignee: Corixa Corporation
    Inventors: Jiangchun Xu, Davin C. Dillon, Jennifer Lynn Mitcham
  • Patent number: 7238338
    Abstract: Disclosed are methods for manufacturing radiohalogen-labeled steroids, nucleosides, nucleotides and proteins, for example, pyrimidines and proteins. Methods according to the example embodiments specific to pyrimidines includes dissolving a halogenated pyrimidine to obtain an initial solution, adding bis(tributyltin) and triphenylphosphine palladium to produce a catalyzed solution, heating the catalyzed solution under conditions sufficient to induce a reaction that produces an intermediate solution including a stannylated pyrimidine compound, removing substantially all of the first solvent from the intermediate solution to obtain an intermediate composition, purifying the resulting solution to obtain a purified composition including a stannylated pyrimidine, reacting the stannylated pyrimidine compound with a radiohalogen in a buffered reaction mixture to produce the radiohalogenated pyrimidine, adding an antioxidant and extracting the radiohalogenated pyrimidine from the reaction mixture.
    Type: Grant
    Filed: June 20, 2002
    Date of Patent: July 3, 2007
    Assignee: Triumf
    Inventor: Jianming Lu
  • Patent number: 7229797
    Abstract: The present invention relates to a method for the in vitro enzymatic synthesis of deoxyribonucleosides and enzymes suitable for this method.
    Type: Grant
    Filed: August 18, 2000
    Date of Patent: June 12, 2007
    Assignee: Institut Pasteur
    Inventors: Wilhelm Tischer, Hans-Georg Ihlenfeldt, Octavian Barzu, Hiroshi Sakamoto, Elisabeth Pistotnik, Philippe Marlière, Sylvie Pochet
  • Patent number: 7148042
    Abstract: A glyoxal-guanosine-group compound is prepared either by reacting glyoxal-guanine with any one of ribose-1-phosphate and 2-deoxyribose-1-phosphate in the presence of purine nucleoside phosphorylase, or by reacting glyoxal-guanine with any one selected from the group consisting of uridine, 2?-deoxyuridine and thymidine, together with phosphate ion, in the presence of purine nucleoside phosphorylase and pyrimidine nucleoside phosphorylase. The glyoxal-guanosine-group compound is then decomposed by alkali, whereby a guanosine-group compound consisting of guanosine and 2?-deoxyguanosine is prepared.
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: December 12, 2006
    Assignee: Yuki Gosei Kogyo Co., Ltd.
    Inventors: Yoichi Mikami, Seiichiro Matsumoto, Yoshinori Hayashi, Toyoki Sato
  • Patent number: 7141397
    Abstract: A glyoxal-guanosine-group compound is prepared either by reacting glyoxal-guanine with any one of ribose-1-phosphate and 2-deoxyribose-1-phosphate in the presence of purine nucleoside phosphorylase, or by reacting glyoxal-guanine with any one selected from the group consisting of uridine, 2?-deoxyuridine and thymidine, together with phosphate ion, in the presence of purine nucleoside phosphorylase and pyrimidine nucleoside phosphorylase. The glyoxal-guanosine-group compound is then decomposed by alkali, whereby a guanosine-group compound consisting of guanosine and 2?-deoxyguanosine is prepared.
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: November 28, 2006
    Assignee: Yuki Gosei Kogyo Co., Ltd.
    Inventors: Yoichi Mikami, Seiichiro Matsumoto, Yoshinori Hayashi, Toyoki Sato
  • Patent number: 7141396
    Abstract: A glyoxal-guanosine-group compound is prepared either by reacting glyoxal-guanine with any one of ribose-1-phosphate and 2-deoxyribose-1-phosphate in the presence of purine nucleoside phosphorylase, or by reacting glyoxal-guanine with any one selected from the group consisting of uridine, 2?-deoxyuridine and thymidine, together with phosphate ion, in the presence of purine nucleoside phosphorylase and pyrimidine nucleoside phosphorylase. The glyoxal-guanosine-group compound is then decomposed by alkali, whereby a guanosine-group compound consisting of guanosine and 2?-deoxyguanosine is prepared.
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: November 28, 2006
    Assignee: Yuki Gosei Kogyo Co., Ltd.
    Inventors: Yoichi Mikami, Seiichiro Matsumoto, Yoshinori Hayashi, Toyoki Sato
  • Patent number: 7038039
    Abstract: A desired isomer is selectively prepared by phosphorolyzing and isomerizing an anomer mixture of a 1-phosphorylated saccharide derivative while crystallizing one of the isomers to displace the equilibrium. Furthermore, using the action of a nucleoside phosphorylase, a nucleoside is prepared from the 1-phosphorylated saccharide derivative obtained and a base with improved stereoselectivity and a higher yield. This process is an anomer-selective process for preparing a 1-phosphorylated saccharide derivative and a nucleoside.
    Type: Grant
    Filed: February 13, 2001
    Date of Patent: May 2, 2006
    Assignee: Mitsui Chemicals, Inc.
    Inventors: Hironori Komatsu, Hirokazu Awano, Nobuyuki Fukazawa, Kiyoshi Ito, Ichirou Ikeda, Tadashi Araki, Takeshi Nakamura, Tamotsu Asano, Junya Fujiwara, Tomoyuki Ando, Katsutoshi Tsuchiya, Kyoko Maruyama, Hideki Umetani, Takahiro Yamauchi, Hitoki Miyake
  • Patent number: 6991924
    Abstract: L-arginine, citrulline and pyrimidine derivatives including orotic acid, uridine, uridine 5?-monophosphate (UMP), cytidine and cytidine 5?-monophosphate (CMP) are produced using a bacterium belonging to the genus Escherichia harboring a mutant carbamoylphosphate synthetase in which the amino acid sequence corresponding to positions from 947 to 951 in a wild type carbamoylphosphate synthetase is replaced with any one of amino acid sequences of SEQ ID NOS: 1 to 9, and feedback inhibition by uridine 5?-monophosphate in the bacterium is desensitized.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: January 31, 2006
    Assignee: Ajinomoto Co., Inc.
    Inventors: Leonid Romanovich Ptitsyn, Sergey Vasil'evich Smirnov, Irina Borisovna Altman, Anna Eugenievna Novikova, Veronika Aleksandrovna Kotliarova, Mikhail Markovich Gusyatiner, Yulia Georgievna Rostova, Tatyana Abramovna Yampolskaya
  • Patent number: 6974865
    Abstract: The present invention is directed to nucleoside monomers wherein the 3?-O atom is replaced with a methylene group. The present invention also provides oligomers comprising a plurality of such monomers which are linked by methylene phosphonate linkages. Further, methods of preparing monomers and oligomers according to the present invention are provided.
    Type: Grant
    Filed: December 18, 2002
    Date of Patent: December 13, 2005
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Muthiah Manoharan, Martin Maier, Haoyun An
  • Patent number: 6951931
    Abstract: Compounds having structure (1) wherein R1 is —H a protecting group, a linker or a binding partner; and R2 and R34 are as defined in the specification. The invention also provides intermediates and methods make the structure (1) compounds, as well as methods to use the compounds as labels in diagnostic assays and to enhance binding to complementary bases.
    Type: Grant
    Filed: November 14, 2002
    Date of Patent: October 4, 2005
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Kuei-Ying Lin, Mark D. Matteucci
  • Patent number: 6900301
    Abstract: Therapeutic oligonucleotide analogues which have improved nuclease resistance and improved cellular uptake are provided. Replacement of the normal phosphorodiester inter-sugar linkages found in natural oligomers with four atom linking groups forms unique di- and poly-nucleosides and nucleotides useful in regulating RNA expression and in therapeutics. Methods of synthesis and use are also disclosed.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: May 31, 2005
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Yogesh Shantilal Sanghvi, Jean Jacques Vasseur, Francoise Debart
  • Patent number: 6890739
    Abstract: The present invention relates to a new use of uridine diphosphate glucose 4-epimerase (also called uridine diphosphate galactose 4-epimerase), and a method of converting uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) to uridine diphosphate N-acetylgalactosamine (UDP-GalNAc) by using the said enzyme. The process for producing UDP-GalNAc by using the uridine diphosphate glucose 4-epimerase and the UDP-GalNAc supply system according to the present invention are practical and efficient, and greatly beneficial to the industries.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: May 10, 2005
    Assignee: Yamasa Corporation
    Inventors: Tomoki Hamamoto, Toshitada Noguchi
  • Patent number: 6858721
    Abstract: The invention provides a method for producing a cytosine nucleoside compound from pentose-1-phosphate and cytosine or a derivative thereof using a nucleoside phosphorylase reactive to cytosine or a bacterium having the enzyme activity. The invention also provides a method for specifically reducing an activity to degrade the substrates or the product, resulting in efficient production of the cytosine nucleoside compound. According to the invention, little by-product is produced in producing cytonucleocide compounds.
    Type: Grant
    Filed: April 30, 2002
    Date of Patent: February 22, 2005
    Assignee: Mitsui Chemicals, Inc.
    Inventors: Tadashi Araki, Ichirou Ikeda, Kaori Matoishi, Reiko Abe, Toshihiro Oikawa, Yasuko Matsuba, Hiroki Ishibashi, Kiyoteru Nagahara, Yasushi Fukuiri
  • Patent number: 6800743
    Abstract: Compounds having structure (1) wherein R1 is —H a protecting group, a linker or a binding partner; and R2 and R34 are as defined in the specification. The invention also provides intermediates and methods make the structure (1) compounds, as well as methods to use the compounds as labels in diagnostic assays and to enhance binding to complementary bases.
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: October 5, 2004
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Kuei-Ying Lin, Mark D. Matteucci
  • Patent number: 6777208
    Abstract: A 2′-deoxyribonucleoside is produced by culturing a microorganism, which is transformed with a gene encoding a ribonucleotide reductase and in which 2′-deoxyribonucleoside degradation activity is decreased or eliminated by disrupting a gene encoding a purine nucleoside phosphorylase on chromosomal DNA, in a medium in which the microorganism can grow to produce the 2′-deoxyribonucleoside.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: August 17, 2004
    Assignee: Ajinomoto Co., Inc.
    Inventors: Seiichi Hara, Naoto Tonouchi, Kenzo Yokozeki
  • Patent number: 6777209
    Abstract: Novel DNA constructs and host cells comprising the same are disclosed. DNA constructs comprise a transcription unit (e.g. operon) comprising DNA sequences encoding for ribonucleotide reductase and thioredoxin or a uridine kinase gene and/or a dCTP deaminase gene. In preferred embodiments the constructs comprising DNA sequences encoding for ribonucleotide reductase and thioredoxin further comprise DNA sequences encoding for thymidylate synthase and/or transcription units comprising sequences encoding for uridine kinase preferably together with dCTP deaminase. In particularly preferred embodiments, the host cells comprise constructs having all of the above characteristics wherein the host cell displays repressed or no uracil DNA glycosylase activity. This may be achieved by removal of the host cell ung gene. Use of host cells in the manufacture of pyrimidine deoxyribonucleotides e.g. thymidine is also disclosed.
    Type: Grant
    Filed: March 6, 2002
    Date of Patent: August 17, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: David Martin Anderson, Lin Liu, Sergey Podkovyrov, Baomin Wang
  • Patent number: 6743910
    Abstract: The invention is a process for stereoselectively producing a dioxolane nucleoside analogue from an anomeric mixture of &bgr; and &agr; anomers represented by the following formula A or formula B: wherein R is selected from the group consisting of C1-6 alkyl and C6-15 aryl and Bz is benzoyl. The process comprises hydrolyzing said mixture with an enzyme selected from the group consisting of Protease N, Alcalase, Savinase, ChiroCLEC-BL, PS-30, and ChiroCLEC-PC to stereoselectively hydrolyze predominantly one anomer to form a product wherein R1 is replaced with H. The process also includes the step of separating the product from unhydrolyzed starting material. Additionally, the functional group at the C4 position is stereoselectively replaced with a purinyl or pyrimidinyl or derivative thereof.
    Type: Grant
    Filed: February 24, 2003
    Date of Patent: June 1, 2004
    Assignee: Biochem Pharma, Inc.
    Inventors: Alex Cimpoia, Yi Fong Wang
  • Publication number: 20040096951
    Abstract: The present invention relates to a crystal comprising the ligand binding pocket of a glycosyltransferase enzyme and optionally a donor molecule or analogue thereof and/or an acceptor molecule or analogue thereof. The present invention also relates to the use of such a crystal to identify ligands capable of modulating glycosyltransferase activity, and the use of such ligands in therapeutic applications.
    Type: Application
    Filed: November 17, 2003
    Publication date: May 20, 2004
    Inventors: Stephen G. Withers, Warren W. Wakarchuk, Natalie C.J. Strynadka, Manuela Dieckelmann, Hoa Ly, Karina Persson
  • Patent number: 6649753
    Abstract: This invention relates to the production of new & stable salts of S-adenosyl-L-methionine SAMe). The source of SAMe used in the salt formation is from chemical process wherein stereoselective methylation of S-adenosyl-L-homocysteine is achieved. The process for the salt preparation is simple, efficient & reproducible on large scale. The new salts were found to be stable at accelerated temperature for minimum 3 months.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: November 18, 2003
    Assignee: Orchid Chemicals & Pharmaceuticals Ltd.
    Inventors: Pandurang Balwant Deshpande, Udayampalam Palanisamy Senthilkumar, Subramaniam Ganesan
  • Patent number: 6620596
    Abstract: A glyoxal-guanosine-group compound is prepared either by reacting glyoxal-guanine with any one of ribose-1-phosphate and 2-deoxyribose-1-phosphate in the presence of purine nucleoside phosphorylase, or by reacting glyoxal-guanine with any one selected from the group consisting of uridine, 2′-deoxyuridine and thymidine, together with phosphate ion, in the presence of purine nucleoside phosphorylase and pyrimidine nucleoside phosphorylase. The glyoxal-guanosine-group compound is then decomposed by alkali, whereby a guanosine-group compound consisting of guanosine and 2′-deoxyguanosine is prepared.
    Type: Grant
    Filed: March 14, 2001
    Date of Patent: September 16, 2003
    Assignee: Yuki Gosei Kogyo Co., Ltd.
    Inventors: Yoichi Mikami, Seiichiro Matsumoto, Yoshinori Hayashi, Toyoki Sato
  • Patent number: 6541625
    Abstract: The invention is a process for stereoselectively producing a dioxolane nucleoside analogue from an anomeric mixture of &bgr; and &agr; anomers represented by the following formula A or formula B: wherein R is selected from the group consisting of C1-6 alkyl and C6-15 aryl and Bz is benzoyl. The process comprises hydrolyzing said mixture with an enzyme selected from the group consisting of Protease N, Alcalase, Savinase, ChiroCLEC-BL, PS-30, and ChiroCLEC-PC to stereoselectively hydrolyze predominantly one anomer to form a product wherein R1 is replaced with H. The process also includes the step of separating the product from unhydrolyzed starting material. Additionally, the functional group at the C4 position is stereoselectively replaced with a purinyl or pyrimidinyl or derivative thereof.
    Type: Grant
    Filed: February 9, 2001
    Date of Patent: April 1, 2003
    Assignee: BioChem Pharma, Inc.
    Inventors: Alex Cimpoia, Yi Fong Wang
  • Publication number: 20020164720
    Abstract: A 2′-deoxyribonucleoside is produced by culturing a microorganism, which is transformed with a gene encoding a ribonucleotide reductase and in which 2′-deoxyribonucleoside degradation activity is decreased or eliminated by disrupting a gene encoding a purine nucleoside phosphorylase on chromosomal DNA, in a medium in which the microorganism can grow to produce the 2′-deoxyribonucleoside.
    Type: Application
    Filed: October 25, 2001
    Publication date: November 7, 2002
    Applicant: Ajinomoto Co., Inc.
    Inventors: Seiichi Hara, Naoto Tonouchi, Kenzo Yokozeki
  • Publication number: 20020127656
    Abstract: The present invention provides polypeptides having pyrimidine glycosylase activity, preferably, pyrimidine glycosylase/AP lyase activity. The polypeptides include a targeting sequence, preferably an exogenous target sequence. The invention includes polynucleotides that include a coding sequence encoding the polypeptides of the present invention. Also provided by the invention are methods of using the polypeptides.
    Type: Application
    Filed: May 23, 2001
    Publication date: September 12, 2002
    Inventors: R. Stephen Lloyd, Amanda K. McCullough, Khoa Nguyen
  • Patent number: 6414127
    Abstract: Compounds having structure (1) wherein R1 is —H a protecting group, a linker or a binding partner; and R2 and R34 are as defined in the specification. The invention also provides intermediates and methods make the structure (1) compounds, as well as methods to use the compounds as labels in diagnostic assays and to enhance binding to complementary bases.
    Type: Grant
    Filed: September 21, 1999
    Date of Patent: July 2, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Kuei-Ying Lin, Mark D. Matteucci
  • Publication number: 20020081666
    Abstract: The present invention discloses nucleic acid enzymes capable of cleaving single-stranded DNA in a site specific manner.
    Type: Application
    Filed: December 20, 2000
    Publication date: June 27, 2002
    Inventor: Gerald F. Joyce
  • Patent number: 6365374
    Abstract: 2′-deoxy-2′-alkylnucleotides useful for stabilizing enzymatic nucleic acid molecules and antisense molecules.
    Type: Grant
    Filed: August 18, 1999
    Date of Patent: April 2, 2002
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Nassim Usman, Alexander Karpeisky, Leonid Beigelman, Anil Modak
  • Patent number: 6344344
    Abstract: Uridine-5′-monophosphate is produced by cultivating in a nutrient medium an uridine-5′-monophosphate producing mutant of coryneform bacterium and which is characterized by at least a resistance to growth inhibition by pyrimidine analogue or a deficiency in uridine degrading activity or combination of said property by protoplast fusion. This method has the advantage of decreased production of uracil. Thus, uridine-5′-monophosphate can be produced in much greater yields, compared with known methods.
    Type: Grant
    Filed: October 25, 2000
    Date of Patent: February 5, 2002
    Assignee: Ajinomoto Co., Inc.
    Inventors: Lyudmila Anatolievna Kazarinova, Vitaliy Arkadievich Livshits, Ekaterina Sergeevna Preobrazhenskaya, Irina Mikhailovna Starovoytova
  • Publication number: 20020004230
    Abstract: The invention concerns stable aqueous solutions containing one or several nucleoside triphosphates wherein the respective solution has a pH value of more than 7.5 and contains no additional substances with a stabilizing effect. The nucleoside triphosphate solutions are used in particular for DNA synthesizing reactions such as e.g. RT-PCR, cycle sequencing, random priming and nick translation. One of the most important applications of such solutions containing deoxynucleoside triphosphates (d-NTP) is their use in the polymerase chain reaction (PCR).
    Type: Application
    Filed: November 19, 1999
    Publication date: January 10, 2002
    Inventors: HANS-GEORG IHLENFELDT, AXEL SCHMIDT, KLAUS MUHLEGGER, VOLKER LEITENBERGER
  • Patent number: 6316228
    Abstract: Methods and compositions, including cell cultures, for producing nucleosides are provided which comprise contacting a nucleoside precursor and a sugar moiety donor with a cell containing a nucleoside phosphorylase. The nucleoside precursor can be a purine or pyrimidine base and the sugar moiety donor can comprise a ribose, a deoxyribose, including 2-deoxyribose, or other sugar of choice. The methods and composition can be used to make thymidine from thymine and 2-deoxyinosine or 2′-deoxyadenosine. Other nucleosides, including those having anticancer and/or antiviral properties, also can be obtained according to the invention.
    Type: Grant
    Filed: July 12, 1999
    Date of Patent: November 13, 2001
    Assignee: The University of Iowa Research Foundation
    Inventors: Vasu Nair, Suresh Pal
  • Publication number: 20010039005
    Abstract: The present invention relates to a method of screening for drug binding to serum proteins by: preparing at least two solutions each including a concentration of a serum protein and a concentration of a candidate drug, wherein the concentration of the candidate drug is different for each of the at least two solutions; exposing each of the at least two solutions to a light source; measuring fluorescent emission by the serum protein or a serum protein-candidate drug complex for each of the at least two solutions upon said exposing; and determining whether a change in fluorescence emission is measured for an increased concentration of the candidate drug, wherein the change in fluorescence emission indicates binding of the candidate drug to the serum protein. A kit useful for performing a fluorimetric screening of drug binding to serum proteins is also disclosed.
    Type: Application
    Filed: January 23, 2001
    Publication date: November 8, 2001
    Inventors: Murali Ramanathan, Marilyn E. Morris
  • Patent number: 6268183
    Abstract: The invention discloses a two-step process for recovery of thuringiensin, comprising adsorbing the thuringiensin from fermentation broth by calcium silicate, and dissociating the thuringiensin by dibasic sodium phosphate. The resulting thuringiensin can be further purified by using semi-preparative HPLC and electrodialysis to remove the excess salts from the recovered thuringiensin solution.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: July 31, 2001
    Assignee: National Science Council
    Inventors: Yew-Min Tzeng, Bing-Lan Liu, Shyuan-Shuenn Huang, Cheng-Ming Liu, Hung-Yieng Tsun
  • Patent number: 6197555
    Abstract: A nucleoside/tide compound having the structure NUC-L-S-LB/LG is described wherein NUC is a nucleoside/tide having a nucleobase portion B, L is a rigid linkage, S is a spacer; and LB/LG is a member of a linkage pair or a label. NUC is attached to L through B such that when B is a purine, L is attached to the 8-position of the purine, when B is 7-deazapurine, L is attached to the 7-position of the 7-deazapurine, and when B is pyrimidine, L is attached to the 5-position of the pyrimidine. In an important aspect of the invention, L has the structure wherein each of n, o and p are integers ranging from 0 to 3, and the sum of n, o and p is at least 2, and each of W, X, Y and Z is selected from the group consisting of carbon and nitrogen. The invention further includes polynucleotide compounds comprising the nucleoside/tide, and primer extension methods utilizing the nucleoside/tide, particularly when used in combination with certain mutant polymerase enzymes.
    Type: Grant
    Filed: December 14, 1999
    Date of Patent: March 6, 2001
    Assignee: The Perkin-Elmer Corporation
    Inventors: Shaheer H. Khan, Barnett B. Rosenblum, Weiguo Zhen, Steven M. Menchen
  • Patent number: 6197552
    Abstract: A process for preparing 2,6-diaminopurine-2′-deoxyriboside and 2′-deoxyguanosine. These compounds may be used as materials for pharmaceuticals, such as antiviral agents and the like, and particularly as starting materials for antisense oligonucleotides.
    Type: Grant
    Filed: November 15, 1998
    Date of Patent: March 6, 2001
    Assignee: Ajinomoto Co., Inc.
    Inventors: Kenzo Yokozeki, Takashi Tsuji, Kunisuke Izawa
  • Patent number: 6127152
    Abstract: There is disclosed a process for producing a nucleoside derivative of the formula [I]: ##STR1## characterized by contacting 2',3',5'-O-triacylribonucleoside derivative of the formula [II]: ##STR2## with an ester hydrolase: (i) capable of regio-selectively deacylating the acyl group at 5'-O-position in the formula [II] above, and(ii) having an amino acid sequence encoded by a gene which hybridizes to a nucleotide sequence encoding an amino acid sequence of SEQ ID NO:1.
    Type: Grant
    Filed: July 30, 1998
    Date of Patent: October 3, 2000
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Hiromichi Ohta, Takeshi Sugai, Takeshi Ishii, Satoshi Mitsuda
  • Patent number: 6090616
    Abstract: A lactamase enzyme having good stability, capable of hydrolysing an enatiomer of the bicyclic lactam, 2-azabicyclo[2.2.1]hept-5-en-3-one, to give (-) lactam and (+) amino acid, has been found in a strain of Comamonas acidivorans. The enzyme has been isolated and cloned, and its structure identified.
    Type: Grant
    Filed: September 3, 1997
    Date of Patent: July 18, 2000
    Assignee: Chirotech Technology, Ltd.
    Inventors: Richard Anthony Wisdom, Caroline Susan Lee, Robert Christopher Brown
  • Patent number: 6087132
    Abstract: The invention relates to a multifunctional nucleoside didesoxyribosyl or nucleoside deoxyribosyl transferase which has one or more of the following additional activities (desoxy) nucleoside kinase, nucleoside reductase desaminase, or DNA polymerase activity. Utilizing the multifunctional enzyme results in a variety of nucleic acid products. These products can be prepared using sequential reactions in a single batch process wherein the sequential reaction can be caused to occur by varying process conditions in a manner which turns on or off the requisite activities causing the sequential reactions to occur. An example of a product prepared in this manner is dideoxyribofuranoside triphosphate. Certain of the resultant products have pharmaceutical activities, e.g. antiviral agents. Lactobacillus leichmannii (DSM 20076) is a source of the multifunctional nucleoside deoxyribosyl transferase.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 11, 2000
    Inventor: Roxana Vasiloiu
  • Patent number: 6028183
    Abstract: Compounds having structure (1) ##STR1## wherein R.sup.1 is --H a protecting group, a linker or a binding partner; and R.sup.2 and R.sup.34 are as defined in the specification. The invention also provides intermediates and methods make the structure (1) compounds, as well as methods to use the compounds as labels in diagnostic assays and to enhance binding to complementary bases.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: February 22, 2000
    Assignee: Gilead Sciences, Inc.
    Inventors: Kuei-Ying Lin, Mark D. Matteucci
  • Patent number: 6017736
    Abstract: The present invention provides a method of preparing stably and at a high yield a purine nucleoside compound by utilizing an exchange reaction of a nucleic acid base which is carried out in the presence of an enzyme, and also provides a microorganism capable of producing uracil thymine dehydrogenase or dihydrouracil dehydrogenase. In preparing the purine nucleoside compound, a pyrimidine nucleoside compound and a purine base are subjected to a base exchange reaction in an aqueous solution containing phosphate ions in the presence of pyrimidine nucleoside phosphorylase and purine nucleoside phosphorylase. The pyrimidine base formed by the base exchange reaction is converted by a microorganism or an enzyme derived from the microorganism into a compound incapable of acting as substrates of pyrimidine nucleoside phosphorylase and purine nucleoside phosphorylase so as to obtain a desired product of purine nucleoside compound.
    Type: Grant
    Filed: July 23, 1998
    Date of Patent: January 25, 2000
    Assignee: Yuki Gosei Kogyo Co., Ltd.
    Inventors: Yoichi Mikami, Seiichiro Matsumoto, Shinjhi Yoshinaka, Yonosuke Sunaga, Ayumi Hasegawa
  • Patent number: 6015697
    Abstract: A method for producing nucleoside-5'-phosphate esters inexpensively and in high yields by phosphorylating a nucleoside with a phospahte group donor using an acid phosphatase having an increased affinity for the nucleoside and/or an increased temperature stability at a pH of pH 3.0 to 5.5, to produce a nucleoside-5'-phosphate ester. Mutant acid phosphatases having increased affinity for nucleosides and/or an enhanced temperature stability are also provided.
    Type: Grant
    Filed: November 21, 1997
    Date of Patent: January 18, 2000
    Assignee: Ajinomoto Co., Inc.
    Inventors: Yasuhiro Mihara, Takashi Utagawa, Hideaki Yamada, Yasuhisa Asano
  • Patent number: 6007992
    Abstract: Compounds having structure (1) ##STR1## wherein R.sup.1 is --H a protecting group, a linker or a binding partner; and R.sup.2 and R.sup.34 are as defined in the specification. The invention also provides intermediates and methods make the structure (1) compounds, as well as methods to use the compounds as labels in diagnostic assays and to enhance binding to complementary bases.
    Type: Grant
    Filed: November 10, 1997
    Date of Patent: December 28, 1999
    Assignee: Gilead Sciences, Inc.
    Inventors: Kuei-Ying Lin, Mark D. Matteucci
  • Patent number: 5948648
    Abstract: A nucleoside/tide compound having the structureNUC--L--S--LB/LGis described wherein NUC is a nucleoside/tide having a nucleobase portion B, L is a rigid linkage, S is a spacer; and LB/LG is a member of a linkage pair or a label. NUC is attached to L through B such that when B is a purine, L is attached to the 8-position of the purine, when B is 7-deazapurine, L is attached to the 7-position of the 7-deazapurine, and when B is pyrimidine, L is attached to the 5-position of the pyrimidine. In an important aspect of the invention, L has the structure ##STR1## wherein each of n, o and p are integers ranging from 0 to 3, and the sum of n, o and p is at least 2, and each of W, X, Y and Z is selected from the group consisting of carbon and nitrogen. The invention further includes polynucleotide compounds comprising the nuclcoside/tide, and primer extension methods utilizing the nucleoside/tide, particularly when used in combination with certain mutant polymerase enzymes.
    Type: Grant
    Filed: May 29, 1998
    Date of Patent: September 7, 1999
    Inventors: Shaheer H. Khan, Barnett B. Rosenblum, Weiguo Zhen, Steven M. Menchen
  • Patent number: 5888777
    Abstract: A process for the preparation of nucleoside diphosphate and triphosphate sugars wherein hydroxyl protective groups are removed enzymatically, with acetylesterase and a process for the preparation of these sugars, which comprises coupling a nucleotide with a sugar-1-phosphate activated with a carbonyl bisazole and then removing the hydroxyl protective groups enzymatically with acetylesterase.
    Type: Grant
    Filed: August 6, 1997
    Date of Patent: March 30, 1999
    Assignee: Novartis AG
    Inventors: Reinhold Oehrlein, Gabriele Baisch
  • Patent number: 5859235
    Abstract: The invention relates to a novel substance with activity against insect pests of the order Diptera. The invention further relates to the substance which acts together with a Bacillus related pesticide, a chemical pesticide and/or a virus with pesticidal properties. The invention further relates to a novel strain(s) of Bacillus thuringiensis which produces such a substance. The invention further relates to pesticidal compositions comprising the substance and a pesticidal carrier, or the substance and a Bacillus related pesticide, a chemical pesticide and/or a virus with pesticidal properties as well as methods of using the pesticidal compositions to control a pest.
    Type: Grant
    Filed: July 11, 1994
    Date of Patent: January 12, 1999
    Assignee: Abbott Laboratories
    Inventors: Chi-Li Liu, William D. Lidster, Carmen Sanchez Lopez
  • Patent number: 5851494
    Abstract: A solid phase synthesis reaction vessel includes a vessel with a first inlet, a second inlet, and an outlet. A first stopcock is disposed within the first inlet and a second stopcock is disposed within the outlet. Solid phase material is prevented from escaping the reaction vessel via the outlet while allowing fluid to flow through the outlet by a frit. In one embodiment, the reaction vessel includes an outer hollow shell surrounding the vessel to allow cooling or heating fluid to flow therein for controlling the temperature in the interior reaction volume. The solid phase synthesis reaction vessel provides for the independent opening and closing of each of the inlets and outlet to provide for various ways of draining the vessel, varying the conditions within the vessel, and/or adding additional materials into the vessel.
    Type: Grant
    Filed: September 4, 1997
    Date of Patent: December 22, 1998
    Assignee: Pharmacopeia, Inc.
    Inventors: Lawrence W. Dillard, Ian Henderson, Michael H. J. Ohlmeyer, John C. Reader
  • Patent number: 5849208
    Abstract: Miniaturized, self-contained apparatus for conducting bio-chemical reactions and analyses is formed in a compact structure made from a substrate which includes a plurality of reaction chambers and a plurality of analysis chambers which are in fluid communication with the reaction chambers. Independently controllable heaters and coolers are positioned in thermal contact with the reaction chambers to permit parallel processing of biological samples at different temperature cycles. The apparatus is especially useful for performing and analyzing the results of a polymerase chain reaction.
    Type: Grant
    Filed: September 7, 1995
    Date of Patent: December 15, 1998
    Assignee: MicroFab Technoologies, Inc.
    Inventors: Donald J. Hayes, David B. Wallace, Christopher J. Frederickson
  • Patent number: 5770716
    Abstract: Substituted propargylethoxyamido nucleosides are disclosed having the structure ##STR1## wherein X is selected from the group consisting of amino alkanoic acid, alkylamino benzoic acid, .alpha.-amino acid, and 4-amino-2-butynoic acid. R.sub.1 and R.sub.2 taken separately are selected from the group consisting of --H, lower alkyl, protecting group, and label; R.sub.3 is selected from the group consisting of --H and lower alkyl. B is a 7-deazapurine, purine, or pyrimidine nucleoside base. When B is purine or 7-deazapurine, the sugar moiety is attached at the N.sup.9 -position of the purine or deazapurine, and when B is pyrimidine, the sugar moiety is attached at the N.sup.1 -position of the pyrimidine.
    Type: Grant
    Filed: April 10, 1997
    Date of Patent: June 23, 1998
    Assignee: The Perkin-Elmer Corporation
    Inventors: Shaheer H. Khan, Steven M. Menchen, Barnett B. Rosenblum
  • Patent number: 5714351
    Abstract: The individual enantiomers of the compounds (Ia), (Ib), (IIa) or (IIb), optionally substituted by non-interfering substituent(s). The novel enantiomers can be obtained by biotransformation. The (Ia) or (IIa) compounds can be used for the synthesis of chiral carbocyclic nucleosides.
    Type: Grant
    Filed: February 13, 1995
    Date of Patent: February 3, 1998
    Assignee: Chiroscience Limited
    Inventors: Christopher Thomas Evans, Stanley Michael Roberts, Karoline Shoberu, Rosemary Mackeith
  • Patent number: 5681702
    Abstract: Methods are provided for substantially reducing background signals encountered in nucleic acid hybridization assays. The method is premised on the elimination or significant reduction of the phenomenon of nonspecific hybridization, so as to provide a detectable signal which is produced only in the presence the target polynucleotide of interest. In addition, a novel method for the chemical synthesis of isoguanosine or 2'-deoxy-isoguanosine is provided. The invention also has applications in antisense and aptamer therapeutics and drug discovery.
    Type: Grant
    Filed: August 30, 1994
    Date of Patent: October 28, 1997
    Assignee: Chiron Corporation
    Inventors: Mark L. Collins, Thomas Horn, Patrick J. Sheridan, Brian D. Warner, Michael S. Urdea
  • Patent number: 5610289
    Abstract: Therapeutic oligonucleotide analogues which have improved nuclease resistance and improved cellular uptake are provided. Replacement of the normal phosphorodiester inter-sugar linkages found in natural oligomers with four atom linking groups forms unique di- and poly- nucleosides and nucleotides useful in regulating RNA expression and in therapeutics. Methods of synthesis and use are also disclosed.
    Type: Grant
    Filed: April 7, 1994
    Date of Patent: March 11, 1997
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Phillip D. Cook, Yogesh S. Sanghvi, Jean J. Vasseur, Francoise Debart